Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Liénard

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 1, 1989
Results of 206 isolated limb perfusions for malignant melanomaF J Lejeune, D Liénard, M el Douaihy, et al.
Cancer Research|February 15, 1997
Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patientsD Valmori, D Liénard, G Waanders, et al.
Seminars in Surgical Oncology|April 21, 1998
Isolated limb perfusion in primary and recurrent melanoma: indications and resultsD Liénard, A M Eggermont, B B Kroon, et al.
Annals of the New York Academy of Sciences|May 31, 1993
Local administration of alpha-MSH exerts a trophic effect on the 200-kDa neurofilament in sciatic rat nerveJ Vadoud Seyedi, D Liénard, L Lespagnard, et al.
International Journal of Cancer|November 27, 1995
Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumorsS Schienk, D Liénard, J Gerain, et al.
Circulatory Shock|August 1, 1994
Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanomaF Lejeune, D Liénard, A Eggermont, et al.
Cytokine|March 7, 1998
Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusionJ Gérain, D Liénard, S Pampallona, et al.
Melanoma Research|August 1, 1997
Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft systemM Furrer, H J Altermatt, H B Ris, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 11, 2007
Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institutionD Roulin, M Matter, P Bady, et al.
Bulletin Du Cancer|July 1, 1995
[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]F Lejeune, D Liénard, A Eggermont, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 1, 1989
Results of 206 isolated limb perfusions for malignant melanomaF J Lejeune, D Liénard, M el Douaihy, et al.
Cancer Research|February 15, 1997
Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patientsD Valmori, D Liénard, G Waanders, et al.
Seminars in Surgical Oncology|April 21, 1998
Isolated limb perfusion in primary and recurrent melanoma: indications and resultsD Liénard, A M Eggermont, B B Kroon, et al.
Annals of the New York Academy of Sciences|May 31, 1993
Local administration of alpha-MSH exerts a trophic effect on the 200-kDa neurofilament in sciatic rat nerveJ Vadoud Seyedi, D Liénard, L Lespagnard, et al.
International Journal of Cancer|November 27, 1995
Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumorsS Schienk, D Liénard, J Gerain, et al.
Circulatory Shock|August 1, 1994
Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanomaF Lejeune, D Liénard, A Eggermont, et al.
Cytokine|March 7, 1998
Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusionJ Gérain, D Liénard, S Pampallona, et al.
Melanoma Research|August 1, 1997
Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft systemM Furrer, H J Altermatt, H B Ris, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 11, 2007
Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institutionD Roulin, M Matter, P Bady, et al.
Bulletin Du Cancer|July 1, 1995
[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]F Lejeune, D Liénard, A Eggermont, et al.
Pageof 8